When I discussed the topic of writing about my experience as an immigrant biotech CEO with Bruce Booth, I had not yet imagined how the global COVID-19 pandemic would change our lives. I initially hesitated to submit it, now that we are in the midst of this crisis – after all there are more important topics we should focus on. But, maybe it is good to get one’s mind off COVID-19 for a few moments.
This blog post was written by Gerhard Koenig, CEO of Arkuda Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Given the hour — 4:30 a.m. in California, 7:30 a.m. in Boston — no one turned on their webcams.
About 180 executives and venture capitalists from large biotech companies and small start-ups alike dialed in to a WebEx call Monday. All were hoping the group chat would help them make big decisions about how to proceed with research, how to raise money from investors — essentially, how to run a biotech company in the time of coronavirus.
The biotech IPO market in 2020 remains strong, despite the volatility and COVID headwinds. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this year. And the queue for companies with active S1’s on file is growing; another dozen or so are likely to go out by mid year.
Standing in the front lines of the Covid-19 response, Alex Harding can see a great future in biotech.
For Alex Harding, being a physician was never going to be enough.
I am a planner. I like to plan most things well in advance; in fact, maybe too far in advance for some. This has often been an asset for me, yet I am pretty sure it can also drive people crazy. A teenager doesn’t like to be asked for the plan to complete a project that is due in 2 weeks. A scientist doesn’t always like to think in decision trees to map out the path of possible outcomes from an assay or a study – and from the assay or study after that.
This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.